Literature DB >> 3179204

Aminoterminal propeptide of type III procollagen in methotrexate-induced liver fibrosis and cirrhosis.

J Risteli1, H Søgaard, A Oikarinen, L Risteli, J Karvonen, H Zachariae.   

Abstract

Twenty-four psoriatic patients on methotrexate were studied with liver biopsies and serum measurements of aminoterminal propeptide of type III procollagen (PIII NP). All but one of nine patients with serum levels of PIII NP above the normal range had liver fibrosis or cirrhosis and no normal liver biopsies were obtained in this group. In contrast, nine normal liver biopsies and two biopsies with minimal fibrosis were found among the 15 patients with normal serum levels of PIII NP. The study indicates that aminoterminal propeptide of type III procollagen can be utilized as a valuable non-invasive marker of fibrogenesis in the liver. This analysis is not specific for the liver, but it seems that the number of liver biopsies probably can be reduced in psoriatics on methotrexate who have normal levels of PIII NP.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3179204     DOI: 10.1111/j.1365-2133.1988.tb03224.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  3 in total

1.  Impact of chemotherapy on collagen metabolism: a study of serum PIIINP (aminoterminal propeptide of type III procollagen) in advanced sarcomas.

Authors:  T A Wiklund; C P Blomqvist; L Risteli; J Risteli; I Elomaa
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

2.  Methotrexate-Related Liver Cirrhosis in Psoriatic Arthritis: A Case Report and Review of the Literature.

Authors:  Maria-Loukia Koutsompina; Maria Pappa; Stratigoula Sakellariou; Chrysoula G Gialouri; George E Fragoulis; Theodoros Androutsakos
Journal:  Mediterr J Rheumatol       Date:  2021-09-07

3.  Type III collagen metabolism in soft tissue sarcomas.

Authors:  T A Wiklund; I Elomaa; C P Blomqvist; L Risteli; J Risteli
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.